Equity and Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Options Roll Forward

A summary of stock option activity during the thirteen weeks ended March 31, 2024 is as follows:

	NUMBER OF OPTIONS	WEIGHTED AVERAGE EXERCISE PRICE		AGGREGATE INTRINSIC VALUE (in thousands)		WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (in years)
Outstanding, December 31, 2023	4,347,186	$	10.22	$	42,965	5.1
Exercised	(318,967)	$	9.87
Outstanding, March 31, 2024	4,028,219	$	10.24	$	57,909	4.9
Exercisable, March 31, 2024	3,128,830	$	10.01	$	45,720	4.7

Schedule of Fair Value Non-vested Options at Grant Dates

A summary of the non-vested stock option activity during the thirteen weeks ended March 31, 2024 is as follows:

	NUMBER OF OPTIONS	WEIGHTED AVERAGE GRANT DATE FAIR VALUE
Nonvested, December 31, 2023	1,234,031	$	7.36
Vested	(334,642)	$	6.52
Nonvested, March 31, 2024	899,389	$	7.67

Schedule of Nonvested Restricted Stock Units Activity

A summary of the Company’s RSU activity during the thirteen weeks ended March 31, 2024 is as follows:

	RESTRICTED STOCK UNITS	WEIGHTED AVERAGE GRANT DATE FAIR VALUE		AGGREGATE INTRINSIC VALUE (in thousands)
Outstanding, December 31, 2023	521,042	$	15.71	$	10,473
Granted	418,251	$	24.79
Vested	(161,859)	$	15.52
Outstanding, March 31, 2024	777,434	$	20.63	$	19,140

Schedule of Unrecognized Stock-based Compensation Expense

The following represents unrecognized stock-based compensation expense and the remaining weighted average vesting period as of March 31, 2024:

	UNRECOGNIZED STOCK-BASED COMPENSATION EXPENSE (in thousands)		REMAINING WEIGHTED AVERAGE VESTING PERIOD (in years)
Stock options	$	2,567	0.6
Restricted stock units	$	15,187	2.4